Nkarta, Inc.
Nkarta, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 8, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 19.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 8, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| April 15, 2027 | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Trial Milestone | Phase 1/Phase 2 |
| October 15, 2028 | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | Trial Milestone | Phase 1/Phase 2 |
Track NKTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open NKTX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 10, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 26, 2026 | 8-K filed: Other event | Filing | — |
| March 25, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 10, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 12, 2025 | Quarterly results filed (8-K) | Earnings | — |
| June 6, 2025 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| May 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| March 31, 2025 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Trial Milestone | Phase 1 |
| October 2, 2024 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.